- Techcyte, headquartered in Orem, Utah, specializes in AI-powered digital diagnostics for anatomic and clinical pathology, positioning itself as a leader in the digital pathology market with its innovative Fusion platform.
- In December 2025, Techcyte was awarded a new AI patent that enhances its training framework for medical imaging algorithms, and it also achieved CE marking under IVDR for its Fusion AP Digital Pathology Platform, further solidifying its market presence.
- Key partnerships include collaborations with Aiforia and Aiosyn to integrate AI-powered functionalities into its Fusion platform, and its Gram Stain Solution was recognized as the 2025 Infectious Disease Testing Solution of the Year by BioTech Breakthrough Awards after validation at Mayo Clinic.
- Techcyte's ideal buyers are hospitals and reference laboratories seeking to modernize their diagnostic workflows; the company addresses the pain of subjective manual microscopy in infectious disease testing, making it a timely solution as digital pathology adoption accelerates.
Techcyte's workforce is structured across 12 departments, with Engineering being the largest, comprising 37 employees. Operations follows with 15 employees, while Information Technology includes 7 staff members. This distribution reflects a strong emphasis on technical capabilities, supported by a balanced presence in operational and IT functions, ensuring efficient service delivery and innovation.
The company's workforce is primarily based in Orem, Utah, which houses 22 employees, followed by Boston, Massachusetts with 4. Other locations include Pleasant Grove, Saint George, and Salt Lake City, each contributing 2 employees. The significant count of 46 employees categorized under 'Other' indicates a distributed workforce model, suggesting a flexible approach to geographic presence and remote work capabilities.
